Delivery Order 36F79719D0224-36C24525N0145
Award Date
10/25/24
Potential Completion Date
10/29/24
Potential Value
$37K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Horizon Therapeutics Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award by the Department of Veterans Affairs (VA) to Horizon Therapeutics USA, Inc. to provide the specialty pharmaceutical KRYSTEXXA 8MG. The contract is a $55,903.32 firm fixed-price delivery order placed against Horizon's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA. Horizon also holds an $18 million Blanket Purchase Agreement (BPA) against the same schedule for other specialty drugs like Ravicti and Buphenyl....
This federal contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract was awarded to Horizon Therapeutics USA, Inc., a global biotechnology company that provides orphan drugs and specialty pharmaceuticals. The contract is a Delivery Order placed against Horizon's existing Multiple Award Schedule contract for Pharmaceuticals and Drugs with the General Services...
The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a delivery order to Horizon Therapeutics USA Inc. for KRYSTEXXA 8MG, a specialty pharmaceutical product. The order, valued at $55,903.32, was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and did not have a set-aside designation. Horizon Therapeutics is a global biotechnology company that provides orphan drugs and specialty pharmaceuticals to support...
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a Delivery Order to Horizon Therapeutics USA Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The contract, with a potential value of $55,903.32, is a Firm Fixed Price order placed against Horizon Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The Delivery Order has an April 17, 2024 completion date and does not have a set-aside designation. Horizon...
The Department of Veterans Affairs Veterans Health Administration awarded a $131,372.30 firm fixed price delivery order to Horizon Therapeutics USA Inc., a foreign-owned for-profit organization, for the provision of KRYSTEXXA medication. This order was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has no set-aside designation. Horizon Therapeutics has a $18 million Blanket Purchase Agreement against the...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order for KRYSTEXXA 8MG to the prime contractor, Horizon Therapeutics USA, Inc. This order, valued at $74,537.76, was placed against Horizon's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The delivery order has an April 17, 2024 completion date and will provide the specialized orphan drug to VHA hospitals and clinics across the country...
This is a $65,686.15 firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc. under the company's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The order is for KRYSTEXXA 8MG/ML, a specialty pharmaceutical used to treat chronic gout. Horizon Therapeutics is a global biotechnology firm that provides critical medications to support healthcare services for veterans through the VA's Veterans...
This delivery order for $55,903.32 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to Horizon Therapeutics USA Inc. against the company's Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The firm fixed price order, with no set-aside designation, is for the medication KRYSTEXXA 8MG and aims to supply VHA hospitals and clinics in La Vergne, Tennessee with this orphan disease treatment through...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Horizon Therapeutics USA Inc. for the drug KRYSTEXXA 8MG/ML VIAL. The order is placed against Horizon's pre-existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The order has a firm fixed price of $74,537.76 and a completion date of May 31, 2024. Horizon Therapeutics USA Inc. is a global biotechnology...